Pharmaceuticals US

US Pulmonary Fibrosis Treatment Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

US Pulmonary Fibrosis Treatment Market Industry Trends and Forecast to 2034: Segmented by (Drug, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

US · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $2.10 Bn Placeholder estimate
Estimate 2025 $2.22 Bn 42.2% of the global market
Projected 2034 $3.62 Bn 63.3% Adds $1.40 Bn over 9 forecast years
CAGR 2025–2034 5.6% Faster than 44% of 180 Pharmaceuticals markets here
Key players 5
  • US is 42.23% of the global market.
  • In North America, the largest is US (this report) at $2.22 Bn.
  • Fastest growing: Canada at 8% a year.
  • US ranks 1st of 2 by size in North America.

Market size projection

US

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.40 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Pulmonary Fibrosis Treatment Market market size by year, US
YearMarket sizeChange that yearSince 2025
2024 (estimate) $2.10 Bn — —
2025 (base) $2.22 Bn +$117.6 Mn —
2026 (forecast) $2.34 Bn +$124.1 Mn +5.6%
2027 (forecast) $2.47 Bn +$131.1 Mn +11.5%
2028 (forecast) $2.61 Bn +$138.4 Mn +17.8%
2029 (forecast) $2.76 Bn +$146.2 Mn +24.4%
2030 (forecast) $2.91 Bn +$154.4 Mn +31.3%
2031 (forecast) $3.07 Bn +$163.0 Mn +38.7%
2032 (forecast) $3.25 Bn +$172.1 Mn +46.4%
2033 (forecast) $3.43 Bn +$181.8 Mn +54.6%
2034 (forecast) $3.62 Bn +$192.0 Mn +63.3%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

US Pulmonary Fibrosis Treatment Market Analysis at a glance
Market size, 2025$2.22 Bn placeholder estimate
Forecast, 2034$3.62 Bn placeholder estimate
Growth (CAGR), 2025–20345.6% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug, type and end user (see all)
Key playersBoehringer Ingelheim GmbH, Roche, United Therapeutics, Bristol-Myers Squibb, Pliant Therapeutics (see all)
Regulator in the USFDASource: US Food and Drug Administration. Checked 14 Nov 2026.
Active clinical trials182 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The US Pulmonary Fibrosis Treatment Market Analysis Executive Summary

Pulmonary fibrosis treatments slow scarring of the lungs, which makes breathing harder over time.

Key segments of the pulmonary Fibrosis Treatment market include drug (Nintedanib, Pirfenidone and Pipeline Therapies) and type (Idiopathic Pulmonary Fibrosis and Progressive Fibrosing ILD).

Bar chart: US Pulmonary Fibrosis Treatment market size, 2024–2034, placeholder estimates. $2.10 Bn in 2024, $2.22 Bn in 2025 and $3.62 Bn in 2034, 5.6% CAGR.
US Pulmonary Fibrosis Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

US Pulmonary Fibrosis Treatment Market Dynamics

Market Growth Drivers

Rising rates of chronic disease linked to diabetes, ageing, smoking and pollution, plus new treatments that slow disease, are driving the pulmonary Fibrosis Treatment market.

Opportunity

Earlier screening, new drug classes and home-based care give the pulmonary Fibrosis Treatment market room to grow.

Market Restraints

Late diagnosis, high prices of new medicines, limited specialist care and poor adherence hold back the pulmonary Fibrosis Treatment market.

Competitive Landscape for Pulmonary Fibrosis Treatment Market in US

The pulmonary Fibrosis Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Pulmonary Fibrosis Treatment Market in US

Pulmonary Fibrosis Treatment in the US: rules, payment and research

New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead.⁠[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).⁠[2] ClinicalTrials.gov lists 182 studies on Pulmonary Fibrosis Treatment that are recruiting, active or about to start in the US.⁠[3]

[1] US Food and Drug Administration. Checked 14 Nov 2026.

[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for pulmonary Fibrosis Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Pulmonary Fibrosis Treatment right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Pulmonary Fibrosis Treatment in context

The US compared

  • Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
  • Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
  • People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 18 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.

Free data on this topic

Inside the US

Quick answers

Frequently asked questions

How big is the Pulmonary Fibrosis Treatment market in the US?
Placeholder estimate: about $2.22 Bn in 2025, rising to about $3.62 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Pulmonary Fibrosis Treatment market in the US growing?
Placeholder estimate: about 5.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Pulmonary Fibrosis Treatment market report cover?
The report splits the market by drug (Nintedanib, Pirfenidone, Pipeline Therapies), type (Idiopathic Pulmonary Fibrosis, Progressive Fibrosing ILD) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Pulmonary Fibrosis Treatment market?
Key players include Boehringer Ingelheim GmbH, Roche, United Therapeutics, Bristol-Myers Squibb and Pliant Therapeutics.
What is driving the Pulmonary Fibrosis Treatment market?
Rising rates of chronic disease linked to diabetes, ageing, smoking and pollution, plus new treatments that slow disease, are driving the pulmonary Fibrosis Treatment market.
Who regulates Pulmonary Fibrosis Treatment in the US?
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead. Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Pulmonary Fibrosis Treatment are running in the US?
182 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
How much research is published on Pulmonary Fibrosis Treatment?
PubMed lists 81 papers on Pulmonary Fibrosis Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in US

See all

Related on respiratory

See the topic